CNBX Pharmaceuticals (8C80) Stock Statistics & Valuation Metrics

CNBX Pharmaceuticals has a market cap or net worth of $4.01K. The enterprise value is €34.17M.

CNBX Pharmaceuticals has 4,196,841 shares outstanding. The number of shares has decreased by -2.65% in one year.

CNBX Pharmaceuticals’s return on equity (ROE) is 0.28 and return on invested capital (ROIC) is 23.51%.

The current PE Ratio of CNBX Pharmaceuticals is -0.27. CNBX Pharmaceuticals’s PEG ratio is <0.01.

In the last 12 months, CNBX Pharmaceuticals had revenue of 130.07K and earned -695.00K in profits. Earnings per share was -0.02.

In the last 12 months, operating cash flow was -138.77K and capital expenditures 0.00, giving a free cash flow of -138.77K billion.

CNBX Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

CNBX Pharmaceuticals upcoming earnings date is ―, TBA Not Confirmed.

CNBX Pharmaceuticals as a current ratio of 0.01, with Debt / Equity ratio of -66.60%

In the past 12 months, CNBX Pharmaceuticals has paid 0.00 in taxes.

CNBX Pharmaceuticals EV to EBITDA ratio is -2.41, with an EV/FCF ratio of -5.93.

CNBX Pharmaceuticals has $45.67K in cash and marketable securities with $1.40M in debt, giving a net cash position of $1.35M billion.

Gross margin is 100.00%, with operating margin of -448.31%, and net profit margin of -534.46%.

The average price target for CNBX Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―